SECsense Logo

Citius Pharmaceuticals 8-K Report: Key Insights from February 14, 2025 Filing

$CTXR
Form 8-K
Filed on: 2025-02-14
Source
Citius Pharmaceuticals 8-K Report: Key Insights from February 14, 2025 Filing

Based on the provided XML section of the financial report, here are the key insights and important information extracted:

  1. Entity Information:
  • Company Name: Citius Pharmaceuticals, Inc.
  • CIK (Central Index Key): 0001506251
  • IRS Employer Identification Number (EIN): 27-3425913
  • Address: 11 Commerce Drive, 1st Floor, Cranford, NJ 07016
  • Phone Number: 908-967-6677
  • Trading Symbol: CTXR (listed on NASDAQ)
  1. Filing Information:
  • Filing Type: 8-K
  • Filing Date: February 14, 2025
  • Period Covered: The report is as of the same date, February 14, 2025.
  1. Financial Metrics:
  • Common Stock: Par value of $0.001 per share.
  1. XML Structure:
  • The report is structured in XBRL format, which is a standard for business reporting. It includes namespaces for different elements such as definitions (dei), currency (iso4217), and linking (link).
  • The context of the report is defined for the specific date, indicating a snapshot of financial data at that time.
  1. Measurement Units:
  • The report includes financial measurements in both USD (U.S. dollars) and shares, indicating that it may contain information about stock performance or quantity.

Insights:

  • The 8-K filing indicates that Citius Pharmaceuticals, Inc. is providing significant information to the SEC, which could relate to material events that shareholders should be aware of.
  • The par value of the common stock suggests that the stock is classified as low-value shares, which is typical for many biotechnology and pharmaceutical companies during their growth phases.
  • The filing date being the same as the period indicates this is likely a current report of a significant event or change.

This section of the financial report provides a brief overview but highlights essential details such as company identification, filing type, and stock characteristics that are crucial for investors and analysts monitoring Citius Pharmaceuticals, Inc.